In Amneal Pharmaceuticals LLC v. Almirall, LLC, the Federal Circuit recently found 35 U.S.C. § 285 did not authorize the Court awarding attorney’s fees for conduct occurring at the PTAB. No. 2020-1106, 2020 WL 2961939, at *2...more
6/22/2020
/ 35 U.S.C. § 285 ,
Abbreviated New Drug Application (ANDA) ,
American Rule ,
Attorney's Fees ,
Fee-Shifting ,
Generic Drugs ,
Inter Partes Review (IPR) Proceeding ,
Litigation Fees & Costs ,
Orange Book ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents ,
Voluntary Dismissals